Paradigm Biopharmaceuticals Ltd Asset Resilience Ratio

Latest as of December 2025: 0.31%

Paradigm Biopharmaceuticals Ltd asset resilience ratio. Paradigm Biopharmaceuticals Ltd (PAR) has an Asset Resilience Ratio of 0.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Paradigm Biopharmaceuticals Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$71.83K
≈ $50.82K USD Cash + Short-term Investments

Total Assets

AU$23.15 Million
≈ $16.38 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Paradigm Biopharmaceuticals Ltd (2016–2025)

Asset resilience ratio of Paradigm Biopharmaceuticals Ltd from 2016 to 2025. This chart shows how Paradigm Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read debt load of Paradigm Biopharmaceuticals Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Paradigm Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Paradigm Biopharmaceuticals Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$71.83K 0.31%
Total Liquid Assets AU$71.83K 0.31%

Asset Resilience Insights

  • Limited Liquidity: Paradigm Biopharmaceuticals Ltd maintains only 0.31% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Paradigm Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Paradigm Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%

Paradigm Biopharmaceuticals Ltd Asset Resilience Ratio by Year (2016–2025)

Paradigm Biopharmaceuticals Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Paradigm Biopharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.00% AU$0.00
≈ $0.00
AU$24.57 Million
≈ $17.39 Million
--
2024-06-30 0.17% AU$46.20K
≈ $32.69K
AU$27.39 Million
≈ $19.38 Million
+0.10pp
2023-06-30 0.07% AU$46.20K
≈ $32.69K
AU$67.07 Million
≈ $47.46 Million
-0.02pp
2022-06-30 0.09% AU$46.20K
≈ $32.69K
AU$50.69 Million
≈ $35.87 Million
+0.04pp
2021-06-30 0.05% AU$46.20K
≈ $32.69K
AU$84.79 Million
≈ $60.00 Million
-0.61pp
2020-06-30 0.66% AU$746.20K
≈ $527.98K
AU$112.36 Million
≈ $79.50 Million
-6.94pp
2019-06-30 7.60% AU$6.50 Million
≈ $4.60 Million
AU$85.51 Million
≈ $60.50 Million
--
2017-06-30 0.00% AU$0.00
≈ $0.00
AU$14.35 Million
≈ $10.15 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$12.35 Million
≈ $8.74 Million
--
pp = percentage points

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology
Market Cap
$91.09 Million
AU$128.74 Million AUD
Market Cap Rank
#19321 Global
#619 in Australia
Share Price
AU$0.25
Change (1 day)
+0.00%
52-Week Range
AU$0.14 - AU$0.39
All Time High
AU$4.35
About

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more